WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2008097661) STABILIZED PICOPLATIN ORAL DOSAGE FORM
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2008/097661    International Application No.:    PCT/US2008/001752
Publication Date: 14.08.2008 International Filing Date: 08.02.2008
IPC:
A61K 33/24 (2006.01), A61K 31/28 (2006.01), A01N 55/02 (2006.01)
Applicants: PONIARD PHARMACEUTICALS, INC. [US/US]; 300 Elliot Avenue West, Suite 500, Seattle, WA 98119-4114 (US) (For All Designated States Except US).
GENZYME CORPORATION [US/US]; 500 Kendall Street, Cambridge, MA 02142 (US) (For All Designated States Except US).
LEIGH, Alistair J. [US/US]; (US) (For US Only).
PROCYSHYN, Christopher A. [CA/CA]; (CA) (For US Only).
WONG, Ernest, S., Y. [US/US]; (US) (For US Only).
GIANDOMENICO, Christen, M. [US/US]; (US) (For US Only)
Inventors: LEIGH, Alistair J.; (US).
PROCYSHYN, Christopher A.; (CA).
WONG, Ernest, S., Y.; (US).
GIANDOMENICO, Christen, M.; (US)
Agent: CLISE, Timothy, B.; Schwegman, Lundberg & Woessner, PA, P.O. Box 2938, Minneapolis, MN 55402 (US)
Priority Data:
60/889,171 09.02.2007 US
60/889,681 13.02.2007 US
Title (EN) STABILIZED PICOPLATIN ORAL DOSAGE FORM
(FR) FORME POSOLOGIQUE ORALE STABILISÉE DE PICOPLATINE
Abstract: front page image
(EN)The invention provides an oral dosage form for the anti-cancer drug picoplatin comprising a core and a coating, the dosage form being free of redox-active metal salts. The core of the tablet is a substantially dry powder comprising about 10 to 60 wt% picoplatin wherein the picoplatin is a particulate of less than about 10 microns average particle diameter, about 40-80 wt% of a filler comprising a substantially water-soluble, water-dispersible, or water-absorbing carbohydrate, and an effective amount of up to about 5 wt% of a lubricant. The dosage form can further include a dispersant.
(FR)L'invention concerne une forme posologique orale de picoplatine, médicament anticancéreux, comprenant un noyau et un enrobage, la forme posologique étant exempte de sels métalliques rédox-actifs. Le noyau du comprimé est une poudre sensiblement sèche comprenant environ de 10 à 60 % en poids de picoplatine, le picoplatine étant une matière particulaire présentant un diamètre moyen des particules inférieur à environ 10 microns, environ de 40 à 80 % en poids d'une charge comprenant un hydrate de carbone sensiblement hydrosoluble, hydrodispersable, ou absorbant l'eau, et une quantité efficace s'élevant jusqu'à environ 5 % en poids d'un lubrifiant. La forme posologique peut également comprendre un dispersant.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)